Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Lung Neoplasms × Dalteparin × Clear all

Phase

Phase 3 2 Phase 4 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Venous Thrombosis 1 Venous Thromboembolism 1 Thromboembolism 1 Thrombocytopenia 1 Pulmonary Embolism 1 Pancreatic Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Hemorrhage 1

Interventions

Propofol 5 Sevoflurane 3 Saline Solution 3 Erlotinib Hydrochloride 3 Carboplatin 3 Acetaminophen 3 Nivolumab 2 Midazolam 2 Lidocaine 2 Docetaxel 2 Cryotherapy 2 Bupivacaine 2 Bronchoscopy 2 Anesthesia, Inhalation 2 trametinib 1 sotorasib 1 pegfilgrastim 1 icotinib 1 endostar protein 1 durvalumab 1 dabrafenib 1 capmatinib 1 camrelizumab 1 beta Carotene 1 atezolizumab 1 Zoledronic Acid 1 Vitamin A 1 Tobacco Use Cessation Devices 1 Sunitinib 1 Sodium Chloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01741506 2015-06-23

COPPVATS

Aarhus University Hospital

Phase 4 Completed

Hemorrhage, Lung Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡